ArticleFrontiers in immunology2026
Intranasal delivery of a polymeric nanoparticle subunit vaccine for the induction of protective immunity against respiratory syncytial virus.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infection in children under the age of 5, worldwide. Maternal vaccination and monoclonal antibodies provide only temporary protection for young children. As antibody wanes, young children remain at risk for severe RSV disease, creating an unmet need for a direct childhood vaccine. We developed an intranasal (IN) subunit vaccine, comprised of a biotinylated nanoparticle and RSV prefusion protein DS-Cav1 (PreF-bNP) with a flexible "plug-n-play" design that enables dose optimization of antigen and adjuvants. In a preimmune RSV mouse model, immunization with intranasal PreF-bNP increased IL-12+ dendritic cells, generated Th1- polarized CD4 effector and tissue resident memory T cells (TRMs) and established antiviral CD8 TRMs in the lung. PreF-bNP-mediated antiviral responses correlated with complete RSV protection up to 8 weeks with reduced mucus production in the lungs. Together, the data presented demonstrate that intranasal PreF-bNP safely protects against RSV infection in young preimmune mice and should be further investigated for future clinical development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.